Rules
Aboutfair balancerisk disclosureindication on labelsubstantiationcomparativemisleading presentationname ingredientsubmissionpre approvalscientific exchangedisclosure
Naturepromotional
Document typeadvertisement
Risk info placementdistinct-part
Communication typeadvertisement
Regulatory classprescription-drug
Drug classprescription
Rx statusprescription
Advertising typeprescription-drug-advertisement
Populationhuman-use
Content triggerliterature-or-study-effectiveness-claim
Materialadvertisement
Content typeadvertisement
Active ingredient counttwo-or-more
Proprietary name basismixture-designation
Established name statusnone-for-mixture-designation
Drug classificationprescription
Labeling scenariosingle-proprietary-name-multiple-preparations-no-established-name
Prescription statusprescription-drug
Ad formattelevision
Intended specieshuman
Exemption statusnon-exempt
Approval pathwayaccelerated
5 of 251 rules — including rules the source does not limit to any one scope
US-FB-019·Section III.C.1, Font Size and StyleAI-verified
Use similar type styles for risk and benefit information
noteneeds human judgment
US-SCI-026·Section V, Q4, item 2.a (CPGs)AI-verified
Shared CPG must be one that is revised as new evidence warrants
noteneeds human judgment
US-ADM-012·Q.8/A.8, concluding paragraphAI-verified
Qualified personnel should review CFL promotional communications before dissemination
notecheckable
US-SUB-009·Section V, Recommendation 3AI-verified
Rely on published peer-reviewed or independent-source data to the greatest extent possible
noteneeds human judgment
US-SUB-010·Section V, Recommendation 3AI-verified
Use reprints only from journals with a stated conflict-of-interest disclosure policy
noteneeds human judgment